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Lab Resource: Single Cell Line 
Generation of a gene-corrected human isogenic iPSC line from an 
Alzheimer’s disease iPSC line carrying the London mutation in APP (V717I) 
Damián Hernández a,*, Stephanie Morgan Schlicht a, Maciej Daniszewski a, Celeste M. Karch b, 
Dominantly Inherited Alzheimer Network (DIAN)1, Alison M. Goate c, Alice Pébay a,d,* 
a Department of Anatomy and Physiology, the University of Melbourne, Parkville, VIC 3010, Australia 
b Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA 
c Department of Genetics and Genomic Sciences, Ronald M. Loeb Center for Alzheimer’s Disease, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New 
York, NY 10029, USA 
d Department of Surgery, Royal Melbourne Hospital, the University of Melbourne, Parkville, VIC 3010, Australia  
A B S T R A C T   
We report the genome-editing of an existing iPSC line carrying the London mutation in APP (V717I) into an iPSC line in which the pathogenic mutation was 
corrected. The resulting isogenic iPSC line maintained pluripotent stem cell morphology, a normal karyotype, expression of pluripotency markers and the ability to 
differentiate into the three germ-layers in vitro.   
Resource Table  
Unique stem cell line 
identifier 
UOMELBi002-A 
Alternative name(s) of 
stem cell line 
F16574c3_A_A1_G8 
Institution The University of Melbourne 
Contact information of 
distributor 
Dr. Damian Hernández, damian.hernandez@unimelb. 
edu.au 
Type of cell line iPSC 
Origin human 
Additional origin info Age: Blinded for publication due to risk of unblinding; 
available upon request 
Sex: Blinded for publication due to risk of unblinding; 
available upon request 
Ethnicity if known: Blinded for publication due to risk 
of unblinding; available upon request 




Episomal for parental iPSC 
Genetic Modification YES 
Type of Modification Gene Correction and silent mutation in one single 
allele (Heterozygous mutation). 
Associated disease Alzheimer’s disease 
Gene/locus APP London mutation (V717I, rs63750264) in exon 
17 of APP. (GRCh38; Chr21:25891784 G > A) 
Method of modification CRISPR Cas9 
(continued on next column)  
(continued ) 
Unique stem cell line 
identifier 
UOMELBi002-A 






Date archived/stock date NA 
Cell line repository/bank NA 
Ethical approval All experimental work performed in this study was 
approved by the University of Melbourne (1545394) 
with the requirements of the National Health & 
Medical Research Council of Australia (NHMRC) and 
conformed with the Declaration of Helsinki.   
1. Resource utility 
The amyloid beta precursor protein (APP) V717I London mutation is 
a dominant inherited mutation that causes early onset Alzheimer’s dis-
ease. APP mutation carriers typically present with an onset at the age of 
45 to 60 years (Bateman et al., 2011). Using isogenic cell pairs with and 
without the disease-causing mutation allows a controlled assessment of 
APP (V717I) in iPSCs and progeny. 
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2. Resource details 
The iPSC line F16574 was previously generated from one individual 
with a mutation in V717I APP (London mutation) (Karch et al., 2018). 
These iPSCs were generated from fibroblasts reprogrammed by nucle-
ofection of episomal vectors containing OCT4, SOX2, KLF4, L-MYC, 
LIN28, and shRNA against p53 with selection of multiple clones and 
subsequent characterisation of pluripotency and genomic integrity 
(Karch et al., 2018). Here, we used the parental iPSC line F16574 clone 3 
for genome editing of the APP locus and correction of the disease- 
causing mutation V717I allowing the generation of isogenic iPSC lines 
for APP mutation (UOMELBi002-A) (Table 1, Fig. 1A). One clone was 
subsequently isolated, expanded and recharacterized as above. The 
CRISPR/Cas9- edited iPSC line showed the typical human pluripotent 
stem cell- morphology and expressed markers of pluripotency TRA-1-60 
and OCT4 (Fig. 1A). Quantification by flow cytometry analysis 
demonstrated 81.3% and 78.3% of live cells were positive for TRA-1-60 
and OCT4 respectively (Fig. 1B). Gene editing correction of the APP 
V717I mutation was confirmed by Sanger DNA sequencing in 
UOMELBi002-A by comparing to the parental FA1657 clone 3 line 
(Fig. 1C). A silent DNA mutation at the PAM sequence (codon TTA 
instead TTG both encoding for Leucine) was included to enhance ho-
mology directed repair efficiency, allow identification of targeted allele 
by Sanger sequencing and to prevent recutting of the edited allele. 
Genomic integrity was assessed by copy number variation analysis of the 
parental iPSCs and the CRISPR/Cas edited iPSCs, represented with log R 
ratio and B allele frequency (Fig. 1D). This analysis confirmed the 
absence of deletions, insertions and aneuploidies. Of note, balanced 
rearrangements cannot be detected by this method. Cell identity was 
confirmed by PCR-based fingerprinting system using short tandem 
repeat (STR) profiling of samples (data not shown). The iPSCs were also 
able to differentiate into the three germ layers, as demonstrated by 
positive immunostaining for endodermal (alpha-fetoprotein, AFP), 
mesodermal (smooth muscle actin, SMA) and ectodermal (NESTIN) 
markers following embryoid body formation (Fig. 1E). 
3. Materials and methods 
3.1. Ethics 
All experimental work performed in this study was approved by the 
Human Research Ethics committees of the University of Melbourne 
(1545394) with the requirements of the National Health & Medical 
Research Council of Australia (NHMRC) and conformed with the 
Declaration of Helsinki (McCaughey et al., 2016). 
3.2. iPSC culture 
The iPSCs were maintained in StemFlex medium (Gibco) using 6- 
well plates pre-coated with vitronectin (Stemcell Technologies). Media 
was changed every second day and cells were passaged with ReleSR 
(Stemcell Technologies) on a weekly basis when colonies reached 80% 
confluency. 
3.3. Generation of isogenic lines 
Genome editing was performed with the CRISPR/Cas9 system in 
combination with a single-stranded DNA (ssDNA, Table 2) to guide the 
single nucleotide correction of the APP V717I mutation by homologous 
recombination. Single guide (sg) RNA sequence was designed as 
described by Zhang’s laboratory (Ran et al., 2013) and selected based on 
the highest on-target and off-target score (Doench et al., 2016; Hsu et al., 
2013). The APP SNP rs63750264 allele (A) of the parental iPSC F16574 
clone 3 line was genetically modified to generate isogenic lines with a 
homozygous G/G nucleotide with the designed sgRNA and the ssDNA 
(Table 2). The ribonucleoprotein (RNP) complex consisting of Cas9 
protein and sgRNA (containing a tracrRNA labelled with a red fluo-
rophore ATTO 550) was assembled in Duplex buffer (all from Integrated 
DNA Technologies). RNP complex was subsequently transfected into 
dissociated iPSCs by electroporation (1200 V, 30 ms, 1 pulse) with the 
Neon transfection system (Invitrogen). After electroporation the cells 
were immediately plated onto vitronectin-plated 6 well plates contain-
ing Stemflex medium supplemented with 10 µM ROCK inhibitor (Revi-
taCell, Gibco). After 48 h, ATTO 550 positive / DAPI negative cells were 
sorted by flow cytometry (BD) (Fig. 1S) and plated at low density for 
clonal selection (1505 cells into 1 well of a six-well plate). Cells were 
screened for SNP editing by PCR and Sanger sequencing (Australian 
Genome Research Facility), from 96 clones that were analysed only one 
clone was re-plated at low density for sub-clonal selection. One colony 
out of ninety-six was subsequently dissociated for sub-clonal selection, 
as to obtain a pure edited population from one out of eight sub-clones 
analysed. The resultant isogenic lines were named UOMELBi002-A. 
Table 1 
Characterization and validation.  
Classification Test Result Data 
Morphology Phase contrast 
brightfield 
morphology pictures 
Normal Fig. 1 panel A 
Phenotype Qualitative analysis 
of pluripotency 
Immunochemistry 
Expression of TRA- 
1–60 and OCT4 





Fig. 1 panel B 
Genotype CNV array Illumina 
HumanCore 
Beadchip array 
which contains over 
300,000 informative 
SNPs with a median 




were cropped to 




Fig. 1 panel D 
Identity STR analysis 10 sites tested, all 
sites matched 
between parental 








Sanger Sequencing Assessment of 
rs63750264 status 
confirmed (A/G) in 
parental and 
UOMELBi002-A 
cell line (G/G) 
Fig. 1 panel C 











A = 0.59 
F16574 clone 
3 = 0.50 
Positive 
control = 3.78 
Negative 










Expression of AFP, 
SMA and NESTIN 
by immunostaining 
Fig. 1 panel E 
Donor screening 
(OPTIONAL) 
HIV 1 + 2 Hepatitis 









HLA tissue typing NA NA  
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Fig. 1. Characterization of UOMELBi002-A.  
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3.4. Virtual karyotype 
Copy number variation analysis of isogenic iPSCs was performed 
using Illumina Infinium CoreExome-24 v1.1, performed by the Victorian 
Clinical Genetics Services (VCGS, Melbourne, Australia). 
3.5. Cell identity 
Short tandem repeat (STR) profiling of samples was performed by 
PCR-based fingerprinting using Promega GenePrint 10 system, and 
performed by the Australian Genome Research Facility (AGRF, Mel-
bourne, Australia). 
3.6. Differentiation to the three-germ layer 
Embryoid bodies were generated using a tri-lineage differentiation 
kit (Stem Cell Technologies). Germ layer differentiation was assessed by 
immunochemistry. 
3.7. Immunocytochemistry 
Cells were fixed with 4% paraformaldehyde and permeabilized with 
0.1% Triton-X (Sigma). Immunocytochemistry was performed using the 
following primary antibodies: mouse anti-TRA-1-60-PE (Invitrogen), 
mouse anti-OCT3/4 (Santa Cruz Biotechnology), smooth muscle actin 
(R&D Systems), mouse anti-NESTIN (Abcam) or rabbit anti-alpha- 
fetoprotein (Sigma-Aldrich) (Table 2). Cells were then immunostained 
with isotype-specific secondary antibodies (Alexa Fluor 568 or 488, Life 
Technologies, Table 2). Nuclei were counterstained using DAPI (Sigma- 
Aldrich) and mounted in Vectashield (Vector Labs). Specificity of the 
staining was verified by the absence of staining in negative controls 
consisting of the appropriate negative control immunoglobulin fraction 
(Dako). Images were acquired on a Zeiss AxioImager M2 fluorescent 
microscope or LMS 880 confocal microscope using ZEN software (Zeiss). 
3.8. Flow cytometry analysis 
Cells were dissociated into single cells with ReleSR and incubated 
with a fixable viability dye (Miltenyi). Then cells were fixed and per-
meabilized with the Inside stain Kit (Miltenyi). Cells were incubated 
with primary antibodies mouse anti-TRA-1-60-PE (Invitrogen) and 
mouse anti-OCT3/4 (Table 2), following incubation with isotype- 
specific secondary antibody (Alexa Fluor 488, Life Technologies, 
Table 2). Unstained cells were used as negative controls. Cells were 
analysed by flow cytometry analysis (Cytoflex S, Beckman Coulter). 
3.9. Mycoplasma testing 
Mycoplasma test was performed using the MycoAlert kit (Lonza) 
following the manufacturer’s instruction. 
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Human fibroblast and stem cell resource from the dominantly inherited Alzheimer 
network. Alzheimer’s Res. Therapy 10 (1). https://doi.org/10.1186/s13195-018- 
0400-0. 
McCaughey, T., Liang, H., Chen, C., Fenwick, E., Rees, G., Wong, R.B., Vickers, J., 
Summers, M., MacGregor, C., Craig, J., Munsie, M., Pébay, A., Hewitt, A., 2016. An 
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